Zymeworks Inc. (ZYME) Stock: Price, Forecast & Analyst Target
Zymeworks Inc. (ZYME) — MoonshotScore 33/100 (Weak band), calculated Nov 18, 2026. Price $26.86 (+3.15%), as of the Nov 19, 2026 trading session; market cap $1.88B.
Educational signal · not a buy or sell recommendation · How to read this
Zymeworks Inc. · ZYME · NASDAQ
Zymeworks Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative biotherapeutics for various cancers.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Zymeworks (ZYME)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a fragile balance sheet — yet price is running hot, well ahead of those stalled fundamentals; treat the move with suspicion, not chase. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Fragile; Valuation: Rich; Growth Durability: Compounding; Momentum: Rising.
- quarterly revenue $28M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 3 reports
- Altman Z 0.71 · Piotroski F 3
Holding back: balance-sheet strain
Helping: business quality, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 37 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 33 | Weak | |
| 33 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $26.86 | |
| Change on the day | +3.15% | |
| Market capitalisation | $1.88B | — |
| Price / earnings (trailing) | 38.57 | |
| Shares traded on the day | 993.1K |
Price & events
Other perspectives
Council score for Zymeworks (ZYME): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Simons-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Zymeworks (ZYME), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Zymeworks Inc. (ZYME) is listed on NASDAQ. It employs 279 people. In Q3 FY2025 it reported revenue of $28M and net income of -$20M. The market values it at $1.88B.
What do the latest results show for Zymeworks (ZYME)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $28M. Against analyst estimates the company has EPS beat 0 of the last 3 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $28M | -$20M | -$0.26 (diluted) |
| Q4 FY2025 | $3M | -$41M | -$0.55 (diluted) |
| Q1 FY2026 | $2M | -$44M | -$0.59 (diluted) |
| Q2 FY2026 | $5M | -$45M | -$0.62 (diluted) |
What are the financial strengths and risks for Zymeworks (ZYME)?
Short answer · as of
The MoonshotScore pillars rate business quality, durable growth, positive momentum as strengths. What is holding it back is balance-sheet strain. The distress and quality screens read Altman Z 0.71 · Piotroski F 3. Trailing ratios: ROE 22.5% · ROA 3.7% · current ratio 3.30 · earnings yield 2.3% · free-cash-flow yield -6.1%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 0.71 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at Zymeworks (ZYME)?
Short answer · as of
Current published price targets run low $32.00 · high $55.00 · consensus $42.71 · median $40.00 against a quoted price of $26.86 (as of Nov 19, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q3 FY2025) was filed Nov 6, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Zymeworks compare with its peers?
Short answer
Zymeworks's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $61.99 Nov 18, 2026 | $1.79B | 98 5-pillar Nov 18, 2026 | |
| $15.13 Nov 18, 2026 | $2.03B | 97 5-pillar Nov 18, 2026 | |
| $14.10 Nov 18, 2026 | $1.54B | 97 5-pillar Nov 18, 2026 | |
| $13.34 Nov 19, 2026 | $2.96B | 97 5-pillar Nov 18, 2026 | |
| $33.11 Nov 18, 2026 | $1.94B | 96 5-pillar Nov 18, 2026 | |
| $18.40 Nov 18, 2026 | $1.31B | 96 5-pillar Nov 18, 2026 | |
| $58.26 Nov 19, 2026 | $2.97B | 95 5-pillar Nov 18, 2026 | |
| $25.57 Nov 18, 2026 | $2.06B | 89 5-pillar Nov 18, 2026 | |
| $47.40 Nov 19, 2026 | $1.41B | 76 5-pillar Nov 18, 2026 | |
| $40.04 Nov 19, 2026 | $1.30B | 69 5-pillar Nov 18, 2026 | |
| $17.83 Nov 18, 2026 | $3.08B | 68 5-pillar Nov 18, 2026 | |
| $13.72 Nov 19, 2026 | $1.96B | 63 5-pillar Nov 18, 2026 | |
| Zymeworks (ZYME) — this page | $26.86 | $1.88B | 33 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $32.00 – $55.00
- Consensus target
- $42.71
- Median target
- $40.00
Consensus record · Captured .
Measured against a quoted price of $26.86 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 9, 2026
- Transactions
- 4
- Identified insiders
- 2
- Purchases
- 0
- Sales
- 1
- Other transactions
- 3
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ZYME in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ZYME in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Zymeworks (ZYME)?
Zymeworks Stock: Key Questions Answered
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for ZYME?
ZYME carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is ZYME a good stock to buy?
Stock Expert AI does not rate ZYME buy, sell or hold. Zymeworks Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ZYME stock price today?
The last price recorded for Zymeworks Inc. (ZYME), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ZYME price target?
The analyst consensus price target for Zymeworks Inc. (ZYME), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the key factors to evaluate for ZYME?
Zymeworks Inc. (ZYME) holds a MoonshotScore in the low range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Zymeworks Inc. does not currently pay a dividend, which is typical for growth-oriented clinical-stage biopharmaceutical companies that reinvest earnings into research and development. Not financial advice.
How frequently does ZYME data refresh on this page?
ZYME's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ZYME's recent stock price performance?
Zymeworks Inc. (ZYME) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ZYME overvalued or undervalued right now?
The trailing P/E of Zymeworks Inc. (ZYME) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ZYME?
Fractional-share availability for Zymeworks Inc. (ZYME) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 19 figures on this page — 15 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com